Following its description in long-term cell cultures derived from the lymph node of a patient with Burkitt's lymphoma (4) the Epstein-Barr virus (EBV) has been considered as the possible causative agent or at least a cofactor in the etiology of Burkitt's tumor (6) . The serological studies associating high EBV antibody titers with lymphoproliferative diseases such as Burkitt's lymphoma (7, 18) , chronic lymphocytic leukemia (17), Hodgkin's disease (12, 14, 15) , and other lymphomas (13) have not clarified the role of this virus in these tumors, and the etiological relationship between EBV and human cancer has been questioned because of the reports of elevated antibody titers in nonmalignant diseases of disordered cellmediated immunity (10, 24 (20) have been associated with elevated EBV titers (10, 12-15, 17, 24) .
MATERIALS AND METHODS
Serum samples were retrieved from 63 patients with disseminated cryptococcosis who were referred to the National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health, Bethesda, Md. All patients selected had been evaluated for the presence of underlying disease, particularly lymphoproliferative disorders, sarcoidosis, and conditions requiring sustained treatment with corticosteroids, and no contributing factors could be detected. Cryptococcin skin tests (1) were performed on 48 of the 63 patients during or after antifungal therapy. A battery of other skin test antigens (candida, trichophyton, mumps, and tuberculin) was used to be certain the patients were not anergic. Anticryptococcal antibodies were also measured as previously described (2) . Sera from 63 normal individuals matched for age and sex were provided by the Virus Cancer Program. In addition, 21 sera were selected from patients with familial Mediterranean fever who had been on the wards of the NIAID at the time of the disseminated cryptococcosis patients. Sera from the three groups of patients were coded and titered for antibody to the EBV-associated viral capsid antigen (6) using a single batch of antigen prepared from the P3HR-1 cell line. Antibody to the EBV-associated early antigen (8) was determined using methods previously described. All sera were read on the same day that the titrations were performed. Previously standardized test sera were coded and also tested blindly in each day's run as an additional quality control.
RESULTS
Analysis of the antibody titers against the EBV-associated viral capsid antigen and early antigen revealed no differences between the sera of the cryptococcosis patients and either of the two control groups (Table 1) . There was no (9, 19) has shown no correlation between the general immune response and EBV titers, and the studies by Papageorgiou and his colleagues have not been confirmed by others. Furthermore, there is evidence that age affects the level of EBV antibody (11, 16) , and it is not certain if the high-titered lepromatous leprosy patients in Papageorgiou's study (23) were the same age as the controls. At the present time, therefore, there has been no conclusive link between EBV and any disease of known etiology, other than infectious mononucleosis.
In evaluating the cause of an elevated EBV titer, several possibilities must be considered. As in infectious mononucleosis, a regular elevation of EBV titers may be indicative of a viral etiology, and EBV remains as a strong candidate in the search for a cause of certain human tumors, particularly lymphomas and nasopharyngeal cancer. A second possibility, one which explains the elevation of EBV antibodies in certain normal individuals, is that the EBV antibody level is controlled by genetically related factors which correlate with susceptibility to cancer (16 
